Human Kidney Spheroids and Monolayers Provide Insights into SARS-CoV-2 Renal Interactions.


Journal

Journal of the American Society of Nephrology : JASN
ISSN: 1533-3450
Titre abrégé: J Am Soc Nephrol
Pays: United States
ID NLM: 9013836

Informations de publication

Date de publication:
09 2021
Historique:
received: 01 11 2020
accepted: 22 04 2021
pubmed: 12 6 2021
medline: 18 9 2021
entrez: 11 6 2021
Statut: ppublish

Résumé

Although coronavirus disease 2019 (COVID-19) causes significan t morbidity, mainly from pulmonary involvement, extrapulmonary symptoms are also major componen ts of the disease. Kidney disease, usually presenting as AKI, is particularly severe among patients with COVID-19. It is unknown, however, whether such injury results from direct kidney infection with COVID-19's causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or from indirect mechanisms. Using We demonstrated that viral entry molecules and high baseline levels of type 1 IFN-related molecules were present in monolayers and kidney spheroids. Although both models support viral infection and replication, they did not exhibit a cytopathic effect and cell death, outcomes that were strongly present in SARS-CoV-2-infected controls (African green monkey kidney clone E6 [Vero E6] cultures). A comparison of monolayer and spheroid cultures demonstrated higher infectivity and replication of SARS-CoV-2 in actively proliferating monolayers, although the spheroid cultures exhibited high er levels of ACE2. Monolayers exhibited elevation of some tubular injury molecules-including molecules related to fibrosis (COL1A1 and STAT6) and dedifferentiation (SNAI2)-and a loss of cell identity, evident by reduction in megalin (LRP2). The three-dimensional spheroids were less prone to such injury. SARS-CoV-2 can infect kidney cells without a cytopathic effect. AKI-induced cellular proliferation may potentially intensify infectivity and tubular damage by SARS-CoV-2, suggesting that early intervention in AKI is warranted to help minimize kidney infection.

Sections du résumé

BACKGROUND
Although coronavirus disease 2019 (COVID-19) causes significan t morbidity, mainly from pulmonary involvement, extrapulmonary symptoms are also major componen ts of the disease. Kidney disease, usually presenting as AKI, is particularly severe among patients with COVID-19. It is unknown, however, whether such injury results from direct kidney infection with COVID-19's causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or from indirect mechanisms.
METHODS
Using
RESULTS
We demonstrated that viral entry molecules and high baseline levels of type 1 IFN-related molecules were present in monolayers and kidney spheroids. Although both models support viral infection and replication, they did not exhibit a cytopathic effect and cell death, outcomes that were strongly present in SARS-CoV-2-infected controls (African green monkey kidney clone E6 [Vero E6] cultures). A comparison of monolayer and spheroid cultures demonstrated higher infectivity and replication of SARS-CoV-2 in actively proliferating monolayers, although the spheroid cultures exhibited high er levels of ACE2. Monolayers exhibited elevation of some tubular injury molecules-including molecules related to fibrosis (COL1A1 and STAT6) and dedifferentiation (SNAI2)-and a loss of cell identity, evident by reduction in megalin (LRP2). The three-dimensional spheroids were less prone to such injury.
CONCLUSIONS
SARS-CoV-2 can infect kidney cells without a cytopathic effect. AKI-induced cellular proliferation may potentially intensify infectivity and tubular damage by SARS-CoV-2, suggesting that early intervention in AKI is warranted to help minimize kidney infection.

Identifiants

pubmed: 34112705
pii: 00001751-202109000-00019
doi: 10.1681/ASN.2020111546
pmc: PMC8729846
doi:

Substances chimiques

Interferon Type I 0
Receptors, Virus 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2242-2254

Informations de copyright

Copyright © 2021 by the American Society of Nephrology.

Références

World Health Organization: WHO Coronavirus (COVID-19) dashboard. Available at: https://covid19.who.int/ . Accessed March 11, 2021
Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TS, et al.: AKI in hospitalized patients with and without COVID-19: A comparison study. J Am Soc Nephrol 31: 2145–2157, 2020
Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al.; Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium Acute kidney injury in patients hospitalized with COVID-19. Kidney Int 98: 209–218, 2020
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al.; China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382: 1708–1720, 2020
Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al.; the Northwell COVID-19 Research Consortium Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 323: 2052–2059, 2020
Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al.: Extrapulmonary manifestations of COVID-19. Nat Med 26: 1017–1032, 2020
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al.: Endothelial cell infection and endotheliitis in COVID-19. Lancet 395: 1417–1418, 2020
Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C: Cytokine storm in COVID-19: The current evidence and treatment strategies. Front Immunol 11: 1708, 2020
Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al.: Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 97: 829–838, 2020
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395: 1054–1062, 2020
Farkash EA, Wilson AM, Jentzen JM: Ultrastructural evidence for direct renal infection with SARS-CoV-2. J Am Soc Nephrol 31: 1683–1687, 2020
Kissling S, Rotman S, Gerber C, Halfon M, Lamoth F, Comte D, et al.: Collapsing glomerulopathy in a COVID-19 patient. Kidney Int 98: 228–231, 2020
Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al.: Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int 98: 219–227, 2020
Braun F, Lütgehetmann M, Pfefferle S, Wong MN, Carsten A, Lindenmeyer MT, et al.: SARS-CoV-2 renal tropism associates with acute kidney injury. Lancet 396: 597–598, 2020
Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al.: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270–273, 2020
Zhang YM, Zhang H: Genetic roadmap for kidney involvement of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Clin J Am Soc Nephrol 15: 1044–1046, 2020
Singh M, Bansal V, Feschotte C: A single-cell RNA expression map of human coronavirus entry factors. Cell Rep 32: 108175, 2020
Larsen CP, Bourne TD, Wilson JD, Saqqa O, Sharshir MA: Collapsing glomerulopathy in a patient with COVID-19. Kidney Int Rep 5: 935–939, 2020
Miller SE, Brealey JK: Visualization of putative coronavirus in kidney. Kidney Int 98: 231–232, 2020
Calomeni E, Satoskar A, Ayoub I, Brodsky S, Rovin BH, Nadasdy T: Multivesicular bodies mimicking SARS-CoV-2 in patients without COVID-19. Kidney Int 98: 233–234, 2020
Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al.: Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 323: 1843–1844, 2020
Bwire GM, Majigo MV, Njiro BJ, Mawazo A: Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: A systematic review and meta-analysis. J Med Virol 93: 719–725, 2021
Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, et al.: Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl) 133: 1039–1043, 2020
Buzhor E, Harari-Steinberg O, Omer D, Metsuyanim S, Jacob-Hirsch J, Noiman T, et al.: Kidney spheroids recapitulate tubular organoids leading to enhanced tubulogenic potency of human kidney-derived cells. Tissue Eng Part A 17: 2305–2319, 2011
Harari-Steinberg O, Omer D, Gnatek Y, Pleniceanu O, Goldberg S, Cohen-Zontag O, et al.: Ex vivo expanded 3D human kidney spheres engraft long term and repair chronic renal injury in mice. Cell Rep 30: 852–869.e4, 2020
KDIGO Clinical Practice Guideline for Acute Kidney Injury, 2012. Avalable at: https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf . Accessed May 1, 2021
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45: 486–552, 2017 28098591
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al.: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APha/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Hypertension 71: e136–e139, 2018]. Hypertension 71: 1269–1324, 2018
Harari-Steinberg O, Metsuyanim S, Omer D, Gnatek Y, Gershon R, Pri-Chen S, et al.: Identification of human nephron progenitors capable of generation of kidney structures and functional repair of chronic renal disease. EMBO Mol Med 5: 1556–1568, 2013
Metsuyanim S, Harari-Steinberg O, Buzhor E, Omer D, Pode-Shakked N, Ben-Hur H, et al.: Expression of Stem Cell Markers in the Human Fetal Kidney 2009. Available at: 10.1371/journal.pone.0006709. Accessed May 1, 2021 10.1371/journal.pone.0006709
Ogando NS, Dalebout TJ, Zevenhoven-Dobbe JC, Limpens RWAL, van der Meer Y, Caly L, et al.: SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid adaptation and cytopathology. J Gen Virol 101: 925–940, 2020
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D: Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181: 281–292.e6, 2020
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al.: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181: 271–280.e8, 2020
Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Du P, et al.: CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct Target Ther 5: 283, 2020
van der Hoek L: Human coronaviruses: What do they cause? Antivir Ther 12[4 Pt B]: 651–658, 2007
Sharma A, Garcia G, Wang Y, Plummer JT, Morizono K, Arumugaswami V, et al.: Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. Cell Reports Med, 1: 100052, 2020
Au WC, Moore PA, LaFleur DW, Tombal B, Pitha PM: Characterization of the interferon regulatory factor-7 and its potential role in the transcription activation of interferon A genes. J Biol Chem 273: 29210–29217, 1998
Ritchie KJ, Hahn CS, Kim KL, Yan M, Rosario D, Li L, et al.: Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med 10: 1374–1378, 2004
Crawford A, Angelosanto JM, Nadwodny KL, Blackburn SD, Wherry EJ: A role for the chemokine RANTES in regulating CD8 T cell responses during chronic viral infection. PLoS Pathog 7: e1002098, 2011
Kumar S: Cellular and molecular pathways of renal repair after acute kidney injury. Kidney Int 93: 27–40, 2018
Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, et al.: A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell 182: 744–753.e4, 2020
Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al.: Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun 11: 3810, 2020
Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, et al.: Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. J Virol 94: e01410–e01420, 2020
Hansrivijit P, Qian C, Boonpheng B, Thongprayoon C, Vallabhajosyula S, Cheungpasitporn W, et al.: Incidence of acute kidney injury and its association with mortality in patients with COVID-19: A meta-analysis. J Investig Med 68: 1261–1270, 2020
Chen YT, Shao SC, Hsu CK, Wu IW, Hung MJ, Chen YC: Incidence of acute kidney injury in COVID-19 infection: A systematic review and meta-analysis. Crit Care 24: 346, 2020
Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, et al.: Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A 117: 7001–7003, 2020
Barr IG, Rynehart C, Whitney P, Druce J: SARS-CoV-2 does not replicate in embryonated hen’s eggs or in MDCK cell lines. Euro Surveill 25: 2020
Chu H, Chan JF-W, Yuen TT-T, Shuai H, Yuan S, Wang Y, et al.: Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: An observational study. Lancet Microbe 1: e14–e23, 2020
Xia H, Cao Z, Xie X, Zhang X, Chen JYC, Wang H, et al.: Evasion of type I interferon by SARS-CoV-2. Cell Rep 33: 108234, 2020
Han Y, Duan X, Yang L, Nilsson-Payant BE, Wang P, Duan F, et al.: Identification of SARS-CoV-2 inhibitors using lung and colonic organoids. Nature 589: 270–275, 2021

Auteurs

Dorit Omer (D)

Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
Pediatric Research Center for Genetics, Development and Environment, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Oren Pleniceanu (O)

Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
Pediatric Research Center for Genetics, Development and Environment, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Yehudit Gnatek (Y)

Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
Pediatric Research Center for Genetics, Development and Environment, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Michael Namestnikov (M)

Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
Pediatric Research Center for Genetics, Development and Environment, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
The Kidney Research Laboratory, The Institute of Nephrology and Hypertension, Sheba Medical Center, Ramat-Gan, Israel.

Osnat Cohen-Zontag (O)

Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
Pediatric Research Center for Genetics, Development and Environment, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Sanja Goldberg (S)

Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
Pediatric Research Center for Genetics, Development and Environment, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Yehudit Eden Friedman (YE)

Department of Medicine E, Sheba Medical Center, Ramat-Gan, Israel.

Nehemya Friedman (N)

Central Virology Laboratory, Ministry of Health, Sheba Medical Center, Ramat-Gan, Israel.

Michal Mandelboim (M)

Central Virology Laboratory, Ministry of Health, Sheba Medical Center, Ramat-Gan, Israel.

Einat B Vitner (EB)

Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.

Hagit Achdout (H)

Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.

Roy Avraham (R)

Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.

Eran Zahavy (E)

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona, Israel.

Tomer Israely (T)

Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel.

Haim Mayan (H)

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Medicine E, Sheba Medical Center, Ramat-Gan, Israel.

Benjamin Dekel (B)

Pediatric Stem Cell Research Institute, Edmond and Lily Sara Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.
Pediatric Research Center for Genetics, Development and Environment, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Division of Pediatric Nephrology, Safra Children's Hospital, Sheba Medical Center, Ramat-Gan, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH